ALA — Arovella Therapeutics Share News
0.000.00%
Last trade - 00:00- AU$61.65m
- AU$47.30m
- AU$0.80m
Brief: Arovella Therapeutics Says Michael Baker Resigns As CEO
Brief: Arovella Therapeutics Says Elizabeth Stoner Will Be Retiring As Interim Chair
Brief: Arovella Therapeutics Says IND For Ala-101 Accepted By FDA
Brief: Arovella Therapeutics Appoints Lachie Mallia As CFO
Australia's Arovella Therapeutics jumps on US FDA application for human trials
Brief: Arovella Therapeutics Files IND Application With US FDA For First-In-Human Phase 1 Trial Of ALA-101
Brief: Arovella Therapeutics Says US Patent Application For Arovella's CAR-INKT Cell Platform To Proceed To Grant
Brief: Arovella Therapeutics Says Thomas Duthy Will Be Retiring As Non-Executive Director & Chairman
Brief: Arovella Therapeutics Announces New Placement Of About A$15 Mln At A$0.125 Per Share
Brief: Arovella Therapeutics Seeks Trading Halt
Brief: Arovella Therapeutics To Raise A$20 Million
Australia's Arovella Therapeutics rises on $12.4 mln clinical trial funding
Brief: Arovella Therapeutics Seeks Trading Halt
Australia's Arovella Therapeutics jumps on positive US FDA feedback
Brief: Arovella Therapeutics Says Termination Of Licence And Supply Agreement With Teva Pharmaceuticals
Australia's Arovella Therapeutics rises on completing process development
Australia's Arovella Therapeutics falls on discounted placement
Brief: Arovella Therapeutics Completes A$12.5M Placement
Brief: Arovella Therapeutics Seeks Trading Halt